Study identifier:D9690C00007
ClinicalTrials.gov identifier:NCT06432764
EudraCT identifier:N/A
CTIS identifier:2024-512992-11-00
A Phase Ib open label positron emission tomography study to assess changes in intestinal [11C]AZ14132516 uptake following administration of multiple doses of AZD7798 to patients with Crohn’s disease.
Crohn disease
Phase 1
No
AZD7798, [11C]AZ14132516
All
12
Interventional
20 Years - 80 Years
Allocation: N/A
Endpoint Classification: -
Intervention Model: Sequential Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Apr 2025 by AstraZeneca
AstraZeneca
-
The purpose of this study is to measure the changes in intestinal uptake of radioligand [11C]AZ14132516 following multiple doses of AZD7798 in participants with Crohn's disease.
Location
Status
Location
Stockholm, Sweden, 14186
Status
Recruiting
Arms | Assigned Interventions |
---|---|
Experimental: AZD7798 Arm consists of up to 2 panels | - |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.